Table 3. Proportion of prostate cancer among men with different DRE statuses and PSA ranges, stratified by PV medians (<60 vs. ≥60 ml).
| PV (ml) | ||
|---|---|---|
| <60 ml | ≥60 ml | |
| Digital rectal examinationa,b | ||
| Negative | 41.8% (38/91) | 15.5% (16/103) |
| Positive | 72.5% (29/40) | 45.5% (10/22) |
| Total | 51.1% (67/131) | 20.8% (26/125) |
| PSA (ng ml−1) | ||
| 10–19.9 | 40.6% (28/69) | 15.1% (16/103) |
| 20–50 | 65.1% (41/63) | 20.8% (26/125) |
| Total | 52.3% (69/132) | 20.2% (26/129) |
Abbreviations: DRE, digital rectal examination; PSA, prostate-specific antigen; PV, prostate volume.
a
Because five (1.9%) subjects were missing DRE data, only 256 subjects were included in the analysis.
b
Prostate hardness or nodule on DRE was defined as ‘positive', and other findings were defined as ‘negative'.